

[Cycloserine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AB01](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Cycloserine

Medicine type

Chemical agent

List type

Core

Additional notes

The square box applies only to listing of cycloserine on the EML.

Formulations

Oral > Solid > dosage form: 250 mg ; 125 mg (EMLc)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[terizidone](#) (ATC codes: [J04AK03](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Cycloserine](#)

DrugBank

[Cycloserine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.